Drugs / LMP744
LMP744
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07025226 | Aug 2025 → Sep 2028 expected | glioma | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT03030417 | Feb 2017 → Oct 2023 | cancer, lymphoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07416188 | Jul 2026 → Dec 2030 expected | IDH-wildtype glioblastoma, brain cancer | National Institute of Neurological Disorders and Stroke (NINDS) | Recruiting | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LMP744 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07025226 ↗ |
| Known as | MJ-III-65 | ChEMBL registry synonym — accepted as the source's own label CHEMBL126159 ↗ |
| Known as | NSC-706743 | ChEMBL registry synonym — accepted as the source's own label CHEMBL126159 ↗ |
| Known as | NSC-706744 | ChEMBL registry synonym — accepted as the source's own label CHEMBL126159 ↗ |
| Known as | Topoisomerase-1 inhibitor lmp744 | ChEMBL registry synonym — accepted as the source's own label CHEMBL126159 ↗ |
| Action | Inhibit | “By blocking this repair process, the drug causes DNA damage so that tumor cells cannot survive.” NCT07025226 ↗ |
| Modality | Small molecule | “Indenoisoquinolone C-MYC/TOPOISOMERASE 1 Inhibitor” NCT07416188 ↗ |
| Route | Intravenous | “LMP744 administered IV QD over 1 hour on days 1-5 followed by 23 days without drug (28-day cycle).” NCT03030417 ↗ |